Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Alnylam Pharmaceuticals, Inc. < Previous 1 2 3 4 Next > Alnylam Issues 2023 Corporate Responsibility Report May 07, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity May 02, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results April 18, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension April 07, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session March 20, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease March 13, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives March 05, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam to Webcast Presentations at Upcoming March Investor Conferences February 27, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity February 15, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results January 29, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s Association January 09, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates January 07, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference January 02, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day December 13, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam to Webcast Virtual R&D Day December 06, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023 November 30, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk November 11, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam to Webcast Presentations at Upcoming November Investor Conferences November 07, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity November 02, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Recognized by Science Magazine as Top Employer for Fifth Consecutive Year October 26, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine October 25, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy October 25, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam to Webcast Conference Call Discussing Third Quarter 2023 Financial Results October 19, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis October 09, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam to Present Additional Data for Patisiran in Patients With the Cardiomyopathy of ATTR Amyloidosis, Including 24-Month Results From the APOLLO-B Phase 3 Study, at the Heart Failure Society of America Annual Scientific Meeting 2023 October 06, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis September 13, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis September 13, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk September 07, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam to Appeal Claim Construction Ruling on Two Patents Asserted Against Moderna August 25, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam to Webcast Presentation at Canaccord Genuity 43rd Annual Growth Conference August 02, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.